WE CLAIMS:

~~1. A method of treating or preventing cancer in a subject, comprising administering to the subject a compound of Formula (I) conjointly with a B-cell lymphoma 2 (BCL-2) inhibitor:~~



(I)

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein,~~

~~Z_1 is an optionally substituted heteroaryl;~~

~~Z_2 is an optionally substituted heterocycloalkyl, optionally substituted heteroaryl or a direct bond;~~

~~R_1 is alkyl, cyano, $-NR_aR_b$ or optionally substituted groups selected from cycloalkyl, aryl or heterocyclyl; wherein the substituent, at each occurrence, independently is alkyl, alkoxy, halogen, hydroxyl, hydroxyalkyl, amino, aminoalkyl, nitro, cyano, haloalkyl, haloalkoxy, $-OCO-CH_2-O$-alkyl, $-OP(O)(O\text{-alkyl})_2$ or $-CH_2-OP(O)(O\text{-alkyl})_2$;~~

~~R_2, at each occurrence, independently is an optionally substituted group selected from alkyl or cycloalkyl; wherein the substituent, at each occurrence, is independently halogen, alkoxy, hydroxyl, hydroxyalkyl, haloalkyl or haloalkoxy;~~

~~R_3, at each occurrence, independently is hydrogen, halogen, alkyl, haloalkyl, haloalkoxy, alkoxy, $-NR_aR_b$, hydroxyl or hydroxyalkyl;~~

~~R_a is hydrogen or alkyl;~~

~~R_b is hydrogen, alkyl, acyl, hydroxyalkyl, $-SO_2$-alkyl or optionally substituted cycloalkyl; and 'm' and 'n' are independently 1 or 2.~~

~~2. The method of claim 1, wherein Z_1 is a 5- or 6-membered heteroaryl.~~

~~3. The method of claim 1 or 2, wherein Z_1 is an optionally substituted heteroaryl, wherein the optional substituent is alkyl.~~

~~4. The method of any preceding claim, wherein Z_1 is tetrazolyl, thienyl, triazolyl, pyrrolyl, pyridyl, pyranyl, pyrazinyl, pyridazinyl, pyrimidyl, imidazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, isothiazolyl, oxazolyl, furanyl and pyrazolyl.~~

~~5. The method of any preceding claim, wherein Z_1 is selected from pyridyl and oxazolyl.~~

~~6. The method of claim 1, wherein the compound is represented by formula (IA)~~



(IA)

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein Z_2, R_1, R_2, R_3, 'm' and 'n' are same as defined in claim 1.~~

~~7. The method of claim 1, wherein the compound is represented by formula (IB)~~



(IB)

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein, Z_2, R_1, R_2, R_3, 'm' and 'n' are same as defined in claim 1.~~

~~8. The method of claim 1, wherein the compound is represented by formula (IC)~~



(IC)

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein Z_2, R_1, R_2, R_3, 'm' and 'n' are same as defined in claim 1.~~

~~9. The method of any preceding claim, wherein Z_2 is a 5- or 6-membered heterocycloalkyl or 5- or 6-membered heteroaryl.~~

~~10. The method of any one of claims 1-8, wherein Z_2 is heterocycloalkyl or a direct bond.~~

~~11. The method of any one of claims 1-9, wherein Z_2 is azetidinyl, oxetanyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,4-dioxanyl, tetrazolyl, thienyl, triazolyl, pyrrolyl, pyridyl, pyranyl, pyrazinyl, pyridazinyl, pyrimidyl, piperazinyl, imidazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, isothiazolyl, oxazolyl, furanyl and pyrazolyl.~~

~~12. The method of any one of claims 1-8, wherein Z_2 is pyridyl, pyrazolyl, pyrrolidinyl, or a direct bond.~~

~~13. The method of any one of claims 1-8, wherein Z_2 is a direct bond.~~

~~14. The method of any preceding claim, wherein m is 1 and n is 1 or 2.~~

~~15. The method of any preceding claim, wherein m and n are each 1.~~

~~16. The method of any preceding claim, wherein R_1 is selected from cyano, cycloalkyl, halogen, $-NR_aR_b$, aryl, and heterocyclyl.~~

~~17. The method of any preceding claim, wherein R_1 is selected from cyano, cycloalkyl, aryl, and heterocyclyl.~~

~~18. The method of any preceding claim, wherein R_1 is selected from cyclopropyl, cyclohexyl, piperidinyl, and morpholinyl.~~

~~19. The method of any one of claims 1-17, wherein R_1 is optionally substituted heterocyclyl; wherein the substituent is halogen, hydroxyl, hydroxyalkyl or amino.~~

~~20. The method of any one of claims 1-17, wherein R_1 is optionally substituted azetidinyl, piperidinyl, morpholinyl, pyrrolidinyl or azepanyl.~~

~~21. The method of any preceding claim, wherein R_1 is optionally substituted piperidinyl or morpholinyl.~~

~~22. The method of any one of claims 1-17, wherein R_1 is optionally substituted phenyl; wherein the substituent is halogen.~~

~~23. The method of any one of claims 1-17, wherein R_1 is cyano or cycloalkyl.~~

~~24. The method of any one of claims 1-18, wherein R_1 is cyclopropyl or cyclohexyl.~~

~~25. The method of any one of claims 1-16, wherein R_1 is -NR_aR_b; R_a is hydrogen; R_b is optionally substituted cycloalkyl; wherein the substituent is hydroxyl.~~

~~26. The method of any preceding claim, wherein R_2 is optionally substituted alkyl and the substituent is alkoxy.~~

~~27. The method of any one of claims 1-25, wherein R_2 is cyclopropyl or cyclopentyl.~~

~~28. The method of any preceding claim, wherein R_3 is hydrogen, halogen, alkyl, alkoxy, -NR_aR_b, hydroxyl or hydroxyalkyl; and R_a and R_b are as defined in claim 1.~~

~~29. The method of any preceding claim, wherein R_3 is selected from hydrogen, halogen, alkyl, alkoxy, and hydroxyl.~~

~~30. The method of any preceding claim, wherein R_3 is selected from hydrogen, alkyl and -NR_aR_b.~~

~~31. The method of any preceding claim, wherein R_3 is H.~~

~~32. The method of claim 1, wherein the compound of formula (I) is selected from:~~

~~N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-6-(1H-pyrazol-4-yl) picolinamide;~~
~~N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl) oxazole-4-carboxamide;~~
~~N-(1-methyl-6-(piperidin-1-yl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl) oxazole-4-carboxamide;~~
~~N-(2-cyclopentyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl) oxazole-4-carboxamide;~~
~~N-(6-cyano-2-cyclopentyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl) oxazole-4-carboxamide;~~
~~N-(2-cyclopentyl-6-cyclopropyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl) oxazole-4-carboxamide;~~
~~N-(2-cyclopentyl-6-cyclopropyl-2H-indazol-5-yl)-6-(1H-pyrazol-4-yl) picolinamide;~~
~~N-(2-cyclopentyl-6-morpholino-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl) oxazole-4-carboxamide;~~
~~6'-amino-N-(2-cyclopentyl-6-morpholino-2H-indazol-5-yl)-[2,3'-bipyridine]-6-carboxamide 2,2,2-trifluoroacetate;~~
~~N-(6-(3-fluorophenyl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-cyclohexyl-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~6'-fluoro-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-[2,3'-bipyridine]-6-carboxamide hydrochloride;~~
~~N-(6-cyclohexyl-2-methyl-2H-indazol-5-yl)-6-(1H-pyrazol-4-yl)picolinamide hydrochloride;~~
~~2'-fluoro-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-[2,3'-bipyridine]-6-carboxamide;~~
~~2-(2-chloropyridin-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~

~~N-(1-cyclopentyl-6-cyclopropyl-1H-indazol-5-yl)-6-(1-methyl-1H-pyrazol-4-yl)picolinamide;~~
~~N-(2-cyclopentyl-6-cyclopropyl-2H-indazol-5-yl)-6-(1-methyl-1H-pyrazol-4-yl)picolinamide;~~
~~6-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~N-(2-cyclopentyl-6-cyclopropyl-2H-indazol-5-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide;~~
~~2-(6-methoxypyridin-3-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide;~~
~~N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-2-(3-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~6-bromo-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~6-chloro-5-methyl-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide~~
~~N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-2-(6-methylpyridin-3-yl)oxazole-4-carboxamide;~~
~~N-(2-cyclopentyl-6-cyclopropyl-2H-indazol-5-yl)-2-(2-methylpyridin-3-yl)oxazole-4-carboxamide;~~
~~N-(2-cyclopentyl-6-cyclopropyl-2H-indazol-5-yl)-2-(3-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(2-cyclopentyl-6-cyclopropyl-2H-indazol-5-yl)-2-(6-methylpyridin-3-yl)oxazole-4-carboxamide;~~
~~6'-amino-3-methyl-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-[2,3'-bipyridine]-6-carboxamide hydrochloride;~~
~~5-methyl-6-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~N-(1-cyclopropyl-6-(piperidin-1-yl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~2-(2-hydroxypyridin-3-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide;~~

~~(S)-6-(3-aminopyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide 2,2,2-trifluoroacetate;~~
~~(S)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~N-(1,6-dicyclopropyl-1H-indazol-5-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide;~~
~~N-(1,6-dicyclopropyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-N-(6-cyclopropyl-1-methyl-1H-indazol-5-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide;~~
~~(R)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~(S)-6-(3-aminopyrrolidin-1-yl)-N-(6-cyclopropyl-1-methyl-1H-indazol-5-yl)picolinamide;~~
~~(R)-6-(3-aminopyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~(R)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide;~~
~~N-(6-cyclopropyl-1-methyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(6-cyclopropyl-1-methyl-1H-indazol-5-yl)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)picolinamide;~~
~~(S)-N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)picolinamide;~~
~~(S)-6-(3-aminopyrrolidin-1-yl)-N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)picolinamide;~~

~~(S)-N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide;~~
~~(S)-N-(6-cyclopropyl-1-methyl-1H-indazol-5-yl)-2-(3-hydroxypyrrolidin-1-yl)oxazole-4-carboxamide;~~
~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(6-cyclopropyl-1-methyl-1H-indazol-5-yl)oxazole-4-carboxamide;~~
~~(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide;~~
~~(S)-N-(6-cyclopropyl-1-methyl-1H-indazol-5-yl)-2-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)oxazole-4-carboxamide;~~
~~(S)-N-(6-cyclopropyl-2-methyl-2H-indazol-5-yl)-2-(3-hydroxypyrrolidin-1-yl)oxazole-4-carboxamide;~~
~~(S)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~6-((2-hydroxypropyl)amino)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(~~ ethylpyr~~-1-yl)-1-methyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(~~ ethylpyr~~-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(3-hydroxyazetidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(1-methyl-6-(~~ ethylpyrid~~-1-yl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(2-methyl-6-(~~ ethylpyrid~~-1-yl)-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(6-(3-hydroxypyrrolidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~

~~(R)-N-(6-(3-hydroxypyrrolidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~N-(6-(3-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(R)-N-(6-(3-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~N-(6-(3-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~N-(6-(azepan-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(azepan-1-yl)-1-methyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(2,3-dimethyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(1,3-dimethyl-6-(piperidin-1-yl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-1-(2-methoxyethyl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-2-(2-methoxyethyl)-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-fluoropiperidin-1-yl)-1-methyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(3-fluoropiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~

~~N-(6-(4-hydroxypiperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(3-(hydroxymethyl)piperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-2,3-dimethyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-acetamidopyridin-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide;~~
~~2-(2-acetamidopyridin-4-yl)-N-(6-(3-fluoropiperidin-1-yl)-2-methyl-2H-indazol-5-yl)oxazole-4-carboxamide;~~
~~2-(2-aminopyridin-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(6-(4-fluoropiperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(((1R,4R)-4-hydroxycyclohexyl)amino)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1-methyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-aminopyridin-4-yl)-N-(6-(4-fluoropiperidin-1-yl)-2-methyl-2H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(6-(4-fluoropiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2H-indazol-5-yl)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)picolinamide;~~
~~2-(2-aminopyridin-4-yl)-N-(6-(4-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1-(2-methoxyethyl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1-methyl-1H-indazol-5-yl)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)picolinamide;~~
~~N-(6-(4-(hydroxymethyl)piperidin-1-yl)-2-(2-methoxyethyl)-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~

~~N-(6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methoxypyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-acetamidopyridin-4-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2H-indazol-5-yl)oxazole-4-carboxamide;~~
~~2-(2-aminopyridin-4-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1-methyl-1H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~2-(2-aminopyridin-4-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-2-methyl-2H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-5-yl)-2-(2-methoxypyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-aminopyridin-4-yl)-N-(6-(3-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~2-(2-methoxypyridin-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide;~~
~~2-(2-aminopyridin-4-yl)-N-(6-(3-fluoropiperidin-1-yl)-2-methyl-2H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~(R)-2-(2-aminopyridin-4-yl)-N-(6-(3-hydroxypyrrolidin-1-yl)-2-methyl-2H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~1-(1,3-dimethyl-5-(2-(2-methylpyridin-4-yl)oxazole-4-carboxamido)-1H-indazol-6-yl)piperidin-4-yl 2-methoxyacetate;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methoxypyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(6-(4-aminopiperidin-1-yl)-1-(2-methoxyethyl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(6-(4-aminopiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1-(2-methoxyethyl)-3-methyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-aminopyridin-4-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)oxazole-4-carboxamide;~~

~~N-(6-(4-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-5-yl)-2-(2-hydroxypyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2,6-dimethylpyridin-4-yl)-N-(6-(4-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-5-yl)oxazole-4-carboxamide;~~
~~(S)-N-(6-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-1-(2-methoxyethyl)-3-methyl-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(1-(2-hydroxyethyl)-6-(4-hydroxypiperidin-1-yl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-aminopiperidin-1-yl)-2-(2-methoxyethyl)-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~2-(2,6-dimethylpyridin-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide hydrochloride;~~
~~2-(2-(dimethylamino)~~ ethylpy~~-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-5-yl)-2-(2-(methylamino)~~ ethylpy~~-4-yl)oxazole-4-carboxamide;~~
~~N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)-2-(2-(methylamino)~~ ethylpy~~-4-yl)oxazole-4-carboxamide;~~
~~N-(6-(4-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-(methylsulfonamido)~~ ethylpy~~-4-yl)-oxazole-4-carboxamide;~~
~~2-(2-(dimethylamino)~~ ethylpy~~-4-yl)-N-(6-(4-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-5-yl)-oxazole-4-carboxamide;~~
~~N-(6-(4-(aminomethyl)piperidin-1-yl)-1-(2-methoxyethyl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2,6-dimethylpyridin-4-yl)-N-(6-(4-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-oxazole-4-carboxamide;~~
~~2-(2,6-dimethylpyridin-4-yl)-N-(6-(4-fluoropiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-oxazole-4-carboxamide;~~
~~Diethyl (1-(1-methyl-5-(2-(2-methylpyridin-4-yl)oxazole-4-carboxamido)-1H-indazol-6-yl)piperidin-4-yl)-phosphate; and~~

~~Diethyl ((1-(2-methyl-5-(2-(2-methylpyridin-4-yl)-oxazole-4-carboxamido)-2H-indazol-6-yl)-piperidin-4-yl)-methyl)-phosphate;~~

~~or a pharmaceutically acceptable salt or a stereoisomer thereof.~~

~~33. The method of claim 1, wherein the compound is selected from:~~

~~N-(2-cyclopentyl-6-morpholino-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)-oxazole-4-carboxamide;~~

~~(R)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)-N-(2-methyl-6-(piperidin-1-yl)-2H-indazol-5-yl)picolinamide;~~

~~N-(6-(4-hydroxypiperidin-1-yl)-2,3-dimethyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide; and~~

~~N-(2-cyclopentyl-6-cyclopropyl-2H-indazol-5-yl)-6-(1-methyl-1H-pyrazol-4-yl)picolinamide.~~

~~34. The method of claim 1, wherein the compound is selected from~~

~~N-(6-(3-fluoropiperidin-1-yl)-2-methyl-2H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~

~~2-(2-aminopyridin-4-yl)-N-(6-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-5-yl)oxazole-4-carboxamide;~~

~~N-(6-(4-(aminomethyl)piperidin-1-yl)-1-(2-methoxyethyl)-1H-indazol-5-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide; and~~

~~(S)-N-(6-cyclopropyl-1-methyl-1H-indazol-5-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide.~~

~~35. A method of treating or preventing cancer in a subject, comprising administering to the subject a compound of Formula (II) conjointly with a B-cell lymphoma 2 (BCL-2) inhibitor:~~



~~(II)~~

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein~~

~~X_1 and X_3 independently are CH or N; X_2 is CR_2 or N; provided one and not more than one of X_1, X_2 or X_3 is N;~~

~~A is O or S;~~

~~Y is $-CH_2-$ or O;~~

~~Z is aryl or heterocyclyl;~~

~~R_1, at each occurrence, is independently halo or optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl or $-NR_aR_b$;~~

~~R_2 is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or $-NR_aR_b$; wherein the substituent is alkyl, amino, halo or hydroxyl;~~

~~R_3, at each occurrence, is alkyl or hydroxyl;~~

~~R_a and R_b are independently hydrogen, alkyl, acyl or heterocyclyl;~~

~~'m' and 'n' are independently 0, 1 or 2;~~

~~'p' is 0 or 1.~~

~~36. The method of claim 35, wherein~~

~~A is O or S;~~

~~Y is $-CH_2-$ or O;~~

~~Z is aryl or heterocyclyl;~~

~~R_1, at each occurrence, is independently halo or optionally substituted heterocyclyl, wherein the substituent is alkyl, aminoalkyl, halo, or $-NR_aR_b$; where R_a and R_b are independently hydrogen, alkyl, or heterocyclyl;~~

~~R_2 is hydrogen, cycloalkyl, heterocyclyl or $-NR_aR_b$;~~

~~'m' is 0; and~~

~~'n' is 1.~~

~~37. The method of claim 35, wherein~~

~~A is O or S;~~

~~Y is $-CH_2-$ or O;~~

~~Z is aryl or heterocyclyl;~~

~~R_1, at each occurrence, is independently halo or optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl or $-NR_aR_b$; where R_a and R_b are independently hydrogen, alkyl, or heterocyclyl;~~

~~R_2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl or $-NR_aR_b$, where the substituent is selected from amino, halo or hydroxyl;~~

~~'m' and 'n' are independently 0, 1 or 2; and~~

~~'p' is 0 or 1.~~

~~38. The method of claim 35, or a pharmaceutically acceptable salt thereof, wherein the group~~  ~~is~~

 ,  ,  ,

 or  ;

~~wherein R_2 is as defined in claim 35.~~

~~39. The method of any one of claims 35-38, wherein Z is aryl or 5- or 6-membered heterocyclyl.~~

~~40. The method of any one of claims 35-38, wherein Z is an optionally substituted heterocyclyl selected from phenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1H-tetrazolyl, oxadiazolyl, triazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, azetidinyl, oxetanyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,4-dioxanyl, dioxidothiomorpholinyl, oxapiperazinyl, oxapiperidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiophenyl, dihydropyranyl and azabicyclo[3.2.1]octanyl; each of which is optionally substituted with alkyl, alkoxy, halo, hydroxyl, hydroxyalkyl or $-NR_aR_b$; and R_a and R_b are independently hydrogen, alkyl or acyl.~~

41. The method of claim 35 represented by formula (IIA):



(IIA)

or a pharmaceutically acceptable salt thereof;

wherein A, Y, R_1, R_2, R_3, 'm', 'p' and 'n' are same as defined in claim 35.

42. The method of claim 41, wherein

A is O or S;

Y is $-CH_2-$ or O;

R_1, at each occurrence, is independently halo or optionally substituted heterocyclyl, wherein the substituent is alkyl, aminoalkyl, halo, or $-NR_aR_b$; where R_a and R_b are independently hydrogen, alkyl, or heterocyclyl;

R_2 is hydrogen, cycloalkyl, heterocyclyl or $-NR_aR_b$;

'm' is 0; and

'n' is 1.

43. The method of claim 41, wherein

A is O or S;

Y is $-CH_2-$ or O;

R_1, at each occurrence, is independently halo or optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl or $-NR_aR_b$; where R_a and R_b are independently hydrogen, alkyl, or heterocyclyl;

R_2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl or $-NR_aR_b$, where the substituent is selected from amino, halo or hydroxyl; and

'm' and 'n' are independently 0, 1 or 2.

44. The method of claim 35, represented by (IIB):



~~(IIB)~~

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein A, Y, R_1, R_2 and 'n' are same as defined in claim 35.~~

~~45. The method of claim 44, wherein~~

~~A is O or S;~~

~~Y is $-CH_2-$ or O;~~

~~R_1, at each occurrence, is independently halo or optionally substituted heterocyclyl, wherein the substituent is alkyl, aminoalkyl, halo, or $-NR_aR_b$; where R_a and R_b are independently hydrogen, alkyl, or heterocyclyl;~~

~~R_2 is hydrogen, cycloalkyl, heterocyclyl or $-NR_aR_b$; and~~

~~'n' is 1.~~

~~46. The method of claim 44, wherein~~

~~A is O or S;~~

~~Y is $-CH_2-$ or O;~~

~~R_1, at each occurrence, is independently halo or optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl or $-NR_aR_b$; where R_a and R_b are independently hydrogen, alkyl, or heterocyclyl;~~

~~R_2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl or $-NR_aR_b$, where the substituent is selected from amino, halo or hydroxyl; and~~

~~'m' and 'n' are independently 0, 1 or 2.~~

~~47. The method of formula (I) according to claim 35, is a compound of formula (IIC)~~



~~(IIC)~~

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein A, Y, R_1, R_2 and 'n' are same as defined in claim 35.~~

~~48. The method of any one of claims 35-47, wherein R_1 is optionally substituted heterocyclyl; wherein the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl, hydroxyalkyl or $-NR_aR_b$; and R_a and R_b are independently hydrogen or acyl.~~

~~49. The method of any one of claims 36-47, wherein R_1 is optionally substituted heterocyclyl; wherein the substituent is alkyl, aminoalkyl, halo, or $-NR_aR_b$; and R_a and R_b are independently hydrogen or acyl.~~

~~50. The method of any one of claims 35-47, wherein R_1 is optionally substituted heterocyclyl; and the substituent is alkyl, aminoalkyl, halo, or $-NR_aR_b$; where R_a and R_b are independently hydrogen, alkyl, or heterocyclyl.~~

~~51. The method of any one of claims 35-47, wherein R_1 is optionally substituted heterocyclyl; and the substituent is alkyl, alkoxy, aminoalkyl, halo, hydroxyl or $-NR_aR_b$; where R_a and R_b are independently hydrogen, alkyl, or heterocyclyl.~~

~~52. The method of any one of claims 48-51, wherein R_1 is pyridyl, pyrazolyl, pyrrolidinyl or piperidinyl.~~

~~53. The method of claim 50, wherein R_1 is optionally substituted pyrazolyl, wherein the substituent is alkyl, hydroxyl or $-NR_aR_b$.~~

~~54. The method of any one of claims 35-47, wherein R_1 is halo.~~

~~55. The method of any one of claims 35-54, wherein R_2 is hydrogen, cycloalkyl, heterocyclyl or NR_aR_b.~~

~~56. The method of any one of claims 35-54, wherein R_2 is hydrogen, cycloalkyl, optionally substituted heterocyclyl or NR_aR_b, where the substituent is selected from amino, halo or hydroxyl.~~

~~57. The method of any one of claims 35-54, wherein R_2 is optionally substituted heterocyclyl selected from piperidinyl, pyrrolidinyl, morpholinyl, piperazinyl, azetidinyl, pyrazolyl, furanyl or azabicyclo[3.2.1]octanyl; wherein the substituent is hydroxyl, halo, alkyl or amino.~~

~~58. The method of any one of claims 35-54, wherein R_2 is piperidinyl, pyrrolidinyl, morpholinyl, or piperazinyl.~~

~~59. The method of any one of claims 35-54, wherein R_2 is hydrogen.~~

~~60. The method of any one of claims 35-54, wherein R_2 is cycloalkyl.~~

~~61. The method of claim 60, wherein R_2 is cyclopropyl.~~

~~62. The method of any one of claims 35-61, wherein R_3 is alkyl.~~

~~63. The method of any one of claims 35-62, wherein m is 0 and p is 1.~~

~~64. The method of any one of claims 35-62, wherein m is 0 or 2, and p is 0 or 1.~~

~~65. The method of claim 35, wherein the compound of formula (II) is selected from:~~

~~6'-amino-N-(2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-[2,3'-bipyridine]-6-carboxamide;~~
~~6'-amino-N-(5-cyclopropyl-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-[2,3'-bipyridine]-6-carboxamide hydrochloride;~~
~~N-(5-cyclopropyl-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~

~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1H-pyrazol-4-yl)picolinamide hydrochloride;~~
~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1H-pyrazol-4-yl)picolinamide;~~
~~2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~6-chloro-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)picolinamide;~~
~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1-methyl-1H-pyrazol-4-yl)picolinamide;~~
~~2-(2-chloropyridin-4-yl)-N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~(S)-2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(~~ ethylpyrid~~-3-ylamino)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~6'-amino-N-(2-morpholinooxazolo[5,4-b]~~ ethylpy~~-5-yl)-[2,3'-bipyridine]-6-carboxamide;~~
~~6'-amino-N-(2-morpholinothiazolo[4,5-c]~~ ethylpy~~-6-yl)-[2,3'-bipyridine]-6-carboxamide;~~
~~6'-amino-N-(2-morpholinothiazolo[5,4-b]~~ ethylpy~~-5-yl)-[2,3'-bipyridine]-6-carboxamide;~~
~~2-(2-methylpyridin-4-yl)-N-(2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~6'-amino-N-(2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-[2,3'-bipyridine]-6-carboxamide;~~
~~N-(2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1H-pyrazol-4-yl)picolinamide;~~
~~3-(4-(aminomethyl)piperidin-1-yl)-5-fluoro-N-(2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)benzamide;~~

~~2-(4-(aminomethyl)piperidin-1-yl)-5-fluoro-N-(2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)benzamide;~~
~~2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1H-pyrazol-4-yl)picolinamide;~~
~~N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1H-pyrazol-4-yl)picolinamide;~~
~~N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(2,5-dimorpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-methylpiperazin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide;~~
~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-3-yl)oxazole-4-carboxamide;~~
~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-hydroxypyridin-3-yl)oxazole-4-carboxamide;~~
~~2-(2-hydroxypyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(6-hydroxypyridin-3-yl)oxazole-4-carboxamide;~~
~~2-(2-methoxypyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~2-(2-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~2-(3-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(3-methylpyridin-4-yl)oxazole-4-carboxamide;~~

~~2-(6-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~6-(1-methyl-1H-pyrazol-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)picolinamide;~~
~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(6-methylpyridin-3-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-aminopyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(R)-N-(5-(3-aminopyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)picolinamide;~~
~~(S)-6-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)picolinamide;~~
~~(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-cyclopropyl-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(3-hydroxypyrrolidin-1-yl)oxazole-4-carboxamide;~~
~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(5-cyclopropyl-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~2-(2-methylpyridin-4-yl)-N-(5-(piperidin-1-yl)-2-(~~ ethylpyrid~~-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(2-(2,6-dimethylmorpholino)-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~

~~N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1-methyl-1H-pyrazol-4-yl)picolinamide hydrochloride;~~
~~6-(1-methyl-1H-pyrazol-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)picolinamide;~~
~~N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-3-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(2-((2S,6R)-2,6-dimethylmorpholino)-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~2-(2-hydroxypyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methoxypyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(6-methoxypyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~2-(2-methoxypyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(6-methylpyridin-3-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~2-(3-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~(S)-6-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)picolinamide;~~
~~(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)picolinamide;~~

~~(S)-6-(3-aminopyrrolidin-1-yl)-N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)picolinamide;~~
~~(S)-N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide;~~
~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-aminopyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide;~~
~~(S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(3-hydroxypyrrolidin-1-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)picolinamide;~~
~~(S)-N-(5-cyclopropyl-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide;~~
~~(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide;~~

~~(S)-N-(5-(~~ ethylpyr~~-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(3-hydroxypyrrolidin-1-yl)picolinamide;~~
~~N-(5-(3-hydroxyazetidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)thiophene-2-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~(S)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide~~
~~(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~N-(5-(~~ ethylpyr~~-1-yl)-2-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-methylpyridin-4-yl)-N-(2-(piperidin-1-yl)-5-(~~ ethylpyrid~~-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(~~ ethylpyrid~~-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~5-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)furan-2-carboxamide;~~
~~N-(5-(azepan-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-aminopyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(5-(~~ ethylpyr~~-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(R)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~

~~(R)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~(S)-6-(1-(2-hydroxypropyl)-1H-pyrazol-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)picolinamide~~
~~N-(5-(4-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide~~
~~N-(5-(4-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride~~
~~N-(5-(1-methyl-1H-pyrazol-4-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(3-fluorophenyl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~N-(5-(3-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide;~~
~~N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide;~~
~~N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(6-methoxypyridin-3-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)thiophene-2-carboxamide;~~
~~N-(5-(~~ ethylpyr~~-1-yl)-2-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-methylpyridin-4-yl)-N-(2-(piperidin-1-yl)-5-(~~ ethylpyrid~~-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~

~~5-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)furan-2-carboxamide;~~
~~N-(5-(~~ ethylpyr~~-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(~~ ethylpyrid~~-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~(R)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~
~~N-(5-(furan-3-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(3-fluoropiperidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-fluoropiperidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-aminopiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-methylpyridin-4-yl)-N-(2-morpholino-5-(1H-pyrazol-4-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~N-(5-(6-fluoropyridin-3-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(2-(3-hydroxypiperidin-1-yl)-5-(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~2-(2-acetamidopyridin-4-yl)-N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~N-(2-(3-hydroxypiperidin-1-yl)-5-(4-hydroxypiperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~

~~2-(2-acetamidopyridin-4-yl)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide;~~
~~2-(2-aminopyridin-4-yl)-N-(5-(3-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide hydrochloride;~~
~~5-(2-aminopyridin-4-yl)-N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)furan-3-carboxamide hydrochloride;~~
~~2-(2-aminopyridin-4-yl)-N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide hydrochloride;~~
~~2-(2-aminopyridin-4-yl)-N-(5-(4-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(5-(2-fluoropyridin-4-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-fluoropiperidin-1-yl)-2-(3-hydroxypiperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-aminopiperidin-1-yl)-2-(3-hydroxypiperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride; and~~
~~N-(5-(2-hydroxypyridin-4-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~

~~or a pharmaceutically acceptable salt or a stereoisomer thereof.~~

~~66. The method of claim 35, wherein the compound of formula (II) is selected from~~

~~6'-amino-N-(2-morpholinooxazolo[5,4-b]~~ ethylpy~~-5-yl)-[2,3'-bipyridine]-6-carboxamide;~~

~~N-(5-(4-hydroxypiperidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~

~~N-(2,5-di(piperidin-1-yl)oxazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1H-pyrazol-4-yl)picolinamide hydrochloride; and~~

~~(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide.~~

~~67. The method of claim 35, wherein the compound of formula (II) is selected from:~~

~~N-(5-(3-fluoropiperidin-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-5-(2-methylpyridin-4-yl)furan-2-carboxamide;~~

~~N-(5-(azepan-1-yl)-2-morpholinothiazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~

~~(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]~~ ethylpy~~-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide; and~~

~~N-(2,5-di(piperidin-1-yl)thiazolo[4,5-b]~~ ethylpy~~-6-yl)-6-(1H-pyrazol-4-yl)picolinamide.~~

~~68. A method of treating or preventing cancer in a subject, comprising administering to the subject a compound of Formula (III) conjointly with a B-cell lymphoma 2 (BCL-2) inhibitor:~~



~~(III)~~

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein,~~

~~Z_1 is optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl or is absent;~~

~~Z_2 is optionally substituted cycloalkyl, aryl or heterocyclyl;~~

~~R_1 is hydrogen, optionally substituted alkyl, amino, halogen, cyano, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;~~

~~R_2 at each occurrence is hydrogen, halogen, amino, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;~~

~~R_3 at each occurrence is hydroxy, halogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl or $-NR_aR_b$;~~

~~R_a and R_b, independently for each occurrence, are hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;~~

~~m, at each occurrence, is 0, 1 or 2; and~~

~~n, at each occurrence, is 0, 1, or 2.~~

~~69. The method of claim 68, wherein Z_1 is an optionally substituted heterocyclyl.~~

~~70. The method of claim 68 or 70, wherein Z_1 is a heterocyclyl selected from tetrazolyl, thienyl, triazolyl, pyrrolyl, pyridyl, pyranyl, pyrazinyl, pyridazinyl, pyrimidyl, imidazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, isothiazolyl, oxazolyl, furanyl, pyrazolyl, benzisoxazolyl, benzothiazolyl, benzofuranyl, benzothienyl, benzotriazinyl, phthalazinyl, thianthrene, dibenzofuranyl, dibenzothienyl, benzimidazolyl, indolyl, isoindolyl, indazolyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, purinyl, pteridinyl, 9H-carbazolyl, α-carboline, indolizinyl, benzoisothiazolyl, benzoxazolyl, pyrrolopyridyl, furopyridinyl, purinyl, benzothiadiazolyl, benzooxadiazolyl, benzotriazolyl, benzotriadiazolyl, carbazolyl, dibenzothienyl, acridinyl and pyrazolopyrimidyl.~~

~~71. The method of any one of claims 68 – 70, represented by formula (IIIA)~~



~~IIIA~~

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein Z_2, R_1, R_2, R_3, m, and n are as defined in claim 68.~~

~~72. The method of any one of claims 68 – 70, represented by formula (IIIB)~~



~~(IIIB)~~

~~or a pharmaceutically acceptable salt thereof;~~

~~wherein, Z_2, R_1, R_2, R_3, m, and n are as defined in claim 68.~~

~~73. The method of any one of claims 68 – 72, wherein Z_2 is a heterocyclyl.~~

~~74. The method of any one of claims 68 – 73, wherein Z_2 is a heterocyclyl selected from azetidinyl, oxetanyl, imidazolidinyl, pyrrolidinyl, oxazolidinyl, thiazolidinyl, pyrazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, 1,4-dioxanyl, tetrazolyl, thienyl, triazolyl, pyrrolyl, pyridinyl, tetrahydropyridinyl, pyranyl, pyrazinyl, pyridazinyl, pyrimidyl, piperazinyl, imidazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, isothiazolyl, oxazolyl, furanyl, pyrazolyl, indolinyl, indolinylmethyl, 2-aza-bicyclo[2.2.2]octanyl, chromanyl, xanthenyl or pyrrolopyridyl.~~

~~75. The method of any one of claims 68 – 74, wherein Z_2 is pyrrolidinyl, piperidinyl, piperazinyl, pyridinyl, pyrimidyl, tetrahydropyridinyl or pyrrolopyridyl.~~

~~76. The method of any one of claims 68 – 75, wherein Z_2 is pyrrolidinyl or pyridinyl.~~

~~77. The method of any one of claims 68 – 76, wherein R_1 is optionally substituted heterocyclyl.~~

~~78. The method of any one of claims 68 – 77, wherein R_1 is heterocyclyl; optionally substituted with halogen, hydroxyl or hydroxyalkyl.~~

~~79. The method of any one of claims 68 – 78, wherein R_1 is optionally substituted azetidinyl, piperidinyl, morpholinyl, pyrrolidinyl or azabicyclooctanyl.~~

~~80. The method of any one of claims 68 – 79, wherein R_1 is piperidinyl.~~

~~81. The method of any one of claims 68 – 80, wherein R_2 is optionally substituted alkyl.~~

~~82. The method of any one of claims 68 – 81, wherein R_2 is alkyl, optionally substituted with heterocyclyl.~~

~~83. The method of any one of claims 68 – 80, wherein R_2 is hydrogen.~~

~~84. The method of any one of claims 68 – 80, wherein R_2 is cyclopropyl.~~

~~85. The method of any one of claims 68 – 84, wherein R_3 is halogen, alkyl, haloalkyl, $-NR_aR_b$, cycloalkyl, hydroxyl or hydroxyalkyl; and R_a and R_b are as defined in claim 113.~~

~~86. The method of any one of claims 68 – 85, wherein R_3 is methyl, hydroxyl, or amino.~~

~~87. The method of any one of claims 68 – 86, wherein R_3 is hydroxyl or amino.~~

~~88. The method of claim 68, wherein~~

~~Z_1 is optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heterocyclyl;~~

~~Z_2 is optionally substituted cycloalkyl, aryl or heterocyclyl;~~

~~R_1 is hydrogen, alkyl, amino, halogen, cyano, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, arylalkyl or heterocyclylalkyl;~~

~~R_2 is amino, alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, arylalkyl or heterocyclylalkyl;~~

~~R_3 is hydroxy, alkyl, alkoxy, or $-NR_aR_b$;~~

~~R_a and R_b, independently for each occurrence, are hydrogen, alkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, arylalkyl or heterocyclylalkyl;~~

~~m is 1; and~~

~~n is 1.~~

~~89. The method of claim 68, wherein~~

~~Z_1 is heterocyclyl;~~

~~Z_2 is heterocyclyl;~~

~~R_1 is optionally substituted heterocyclyl;~~

~~R_2 is alkyl;~~

~~R_3 is hydroxy, alkyl, or amino;~~

~~m is 1; and~~

~~n is 1.~~

~~90. The method of claim 68, wherein the compound of formula (III) is selected from:~~

~~N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)picolinamide;~~
~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)oxazole-4-carboxamide;~~
~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)oxazole-4-carboxamide;~~
~~(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)oxazole-4-carboxamide;~~
~~(S)-6-(3-aminopyrrolidin-1-yl)-N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)picolinamide~~
~~(S)-6-(3-aminopyrrolidin-1-yl)-N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)picolinamide;~~
~~(S)-6-(3-hydroxypyrrolidin-1-yl)-N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)picolinamide;~~
~~(S)-2-(3-hydroxypyrrolidin-1-yl)-N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(5-(3-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(5-(3-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(5-(3-fluoropiperidin-1-yl)-2-methyl-2H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(2-acetamidopyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;~~
~~N-(5-(3-fluoropiperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~

~~N-(5-(4-hydroxypiperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(2-aminopyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-fluoropiperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~N-(5-(4-(hydroxymethyl)piperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(2,6-dimethylpyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;~~
~~(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(2-aminopyridin-3-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide Hydrochloride;~~
~~6-((S)-3-hydroxypyrrolidin-1-yl)-N-(5-(~~I~~-3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)picolinamide;~~
~~6-((S)-3-hydroxypyrrolidin-1-yl)-N-(5-((S)-3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl) picolinamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(1H-pyrrolo[2,3-b]~~ ethylpy~~-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(2-amino-3-fluoropyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;~~
~~(R)-2-(2-aminopyridin-3-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(4-methylpiperazin-1-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(piperazin-1-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-N-(1-ethyl-5-(3-hydroxypyrrolidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~

~~(S)-N-(1-cyclopropyl-5-(3-hydroxypyrrolidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(1,2,3,6-tetrahydropyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyrimidin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-4-methyl-2-(2-methylpyridin-4-yl)-oxazole-5-carboxamide hydrochloride;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(piperidin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(5-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-~~ ethylpyridine~~-4-yl)-oxazole-5-carboxamide;~~
~~N-(5-(4-hydroxy-4-(hydroxymethyl)piperidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-5-methyl-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide;~~
~~(S)-2-(2-ethylpyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide;~~
~~2-(2-aminopyridin-4-yl)-N-(5-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-6-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-(piperidin-4-ylmethyl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(5-(4-(hydroxymethyl)piperidin-1-yl)-1,3-dimethyl-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~
~~(S)-2-(2-cyclopropylpyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide hydrochloride;~~
~~N-(5-(4-hydroxypiperidin-1-yl)-2-methyl-2H-indazol-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride; and~~
~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride;~~

~~or a pharmaceutically acceptable salt or a stereoisomer thereof.~~

~~91. The method of claim 68, wherein the compound of formula (III) is selected from:~~

~~(S)-2-(3-aminopyrrolidin-1-yl)-N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)oxazole-4-carboxamide;~~

~~6-((S)-3-hydroxypyrrolidin-1-yl)-N-(5-((S)-3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-picolinamide;~~

~~(S)-N-(1-ethyl-5-(3-hydroxypyrrolidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride; and~~

~~(S)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)-2-(2-methylpyrimidin-4-yl)oxazole-4-carboxamide hydrochloride.~~

~~92. The method of claim 68, wherein the compound of formula (III) is selected from:~~

~~(S)-2-(2-cyclopropylpyridin-4-yl)-N-(5-(3-hydroxypyrrolidin-1-yl)-1-methyl-1H-indazol-6-yl)oxazole-4-carboxamide hydrochloride;~~

~~(S)-N-(1-cyclopropyl-5-(3-hydroxypyrrolidin-1-yl)-1H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride;~~

~~N-(2-methyl-5-(piperidin-1-yl)-2H-indazol-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide hydrochloride; and~~

~~(S)-6-(3-aminopyrrolidin-1-yl)-N-(1-methyl-5-(piperidin-1-yl)-1H-indazol-6-yl)picolinamide.~~

~~93. The method of any preceding claim, wherein the cancer is diffuse large B-cell lymphoma (DLBCL) or Waldenstrom's macroglobulinemia (WM).~~

~~94. The method of claim 93, wherein the DLBCL or WM is characterized by a L265P mutation in MYD88.~~

~~95. The method of claim 93, wherein the method is for treating or preventing DLBCL.~~

~~96. The method of claim 95, wherein the DLBCL is the activated B-cell subtype DLBCL.~~

~~97. The method of claim 94, wherein the method is for treating or preventing WM.~~

~~98. The method of any one of claim 1-92, wherein the cancer is a non-Hodgkin's lymphoma.~~

~~99. The method of claim 98, wherein the non-Hodgkin's lymphoma is selected from mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CNS lymphoma, and testicular lymphoma.~~

~~100. The method of any one of claims 1-92, wherein the cancer is leukemia.~~

~~101. The method of claim 100, wherein the leukemia is acute myeloid leukemia (AML).~~

~~102. The method of claim 100, wherein the leukemia is acute lymphoblastic leukemia (ALL).~~

~~103. The method of claim 100, wherein the leukemia is chronic lymphocytic leukemia (CLL).~~

~~104. The method of claim 100, wherein the leukemia is chronic myelogenous leukemia (CML).~~

~~105. The method of claim 100, wherein the cancer is a myelodysplastic syndrome.~~

~~106. The method of claim 105, wherein the myelodysplastic syndrome is selected from refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.~~

~~107. The method of any one of claim 1-92, wherein the cancer is a myeloproliferative neoplasm.~~

~~108. The method of claim 107, wherein the myeloproliferative neoplasm is selected from chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), polycythemia vera (PCV), primary myelofibrosis, essential thrombocythemia, chronic eosinophilic leukemia, and mastocytosis.~~

~~109. The method of any one of claim 1-92, wherein the cancer is a solid malignant tumor.~~

~~110. The method of claim 109, wherein the solid malignant tumor is selected from biliary cancer, cholangiocarcinoma, bladder cancer, breast cancer, adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast, brain cancer, meningioma, glioma, astrocytoma, oligodendroglioma, glioblastoma, medulloblastoma, cervical cancer, cervical adenocarcinoma, colorectal cancer, colon cancer, rectal cancer, colorectal adenocarcinoma, gastric cancer, stomach adenocarcinoma, gastrointestinal stromal tumor (GIST), head and neck cancer, head and neck squamous cell carcinoma, oral cancer, oral squamous cell carcinoma (OSCC), kidney cancer, nephroblastoma, Wilms' tumor, renal cell carcinoma, liver cancer, hepatocellular cancer (HCC), malignant hepatoma, lung cancer, bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung, neuroblastoma, neurofibroma, neurofibromatosis (NF) type 1 or type 2, schwannomatosis, neuroendocrine cancer, gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor, osteosarcoma, ovarian cancer, cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma, pancreatic cancer, pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), prostate cancer, prostate adenocarcinoma, skin cancer, squamous cell carcinoma (SCC), keratoacanthoma (A), melanoma, basal cell carcinoma (BCC), malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma, and osteosarcoma.~~

~~111. The method of claim 109, wherein the solid malignant tumor is breast cancer or pancreatic cancer.~~

~~112. The method of any preceding claim, wherein the BCL-2 inhibitor is venetoclax.~~

~~113. The method of any preceding claim, wherein conjointly administering the BCL-2 inhibitor provides improved efficacy relative to separately administering the compound of formula (I), the compound of formula (II), or the compound of formula (III), and the BCL-2 inhibitor.~~

~~114. The method of any preceding claim, wherein conjointly administering the BCL-2 inhibitor provides a synergistic effect.~~

~~115. The method of any one preceding claim, wherein the compound of formula (I), the compound of formula (II), or the compound of formula (III), and the BCL-2 inhibitor are administered simultaneously.~~

~~116. The method of any of claims 1-114, wherein the BCL-2 inhibitor is administered within about 5 minutes to within about 168 hours prior to or after administration of the compound of formula (I), the compound of formula (II), or the compound of formula (III).~~

1. Use of a compound in the manufacture of a medicament for treating cancer, wherein the medicament is for conjoint administration with venetoclax and the compound is:



or a pharmaceutically acceptable salt thereof.

2. The use of claim 1, wherein the compound is 

.

3. The use of claim 1, wherein the compound is a pharmaceutically acceptable salt of



.

4. The use of any one of claims 1-3, wherein the cancer is DLBCL.

5. The use of claim 4, wherein the DLBCL is the activated B-cell subtype DLBCL.

6. The use any one of claims 1-3, wherein the cancer is WM.

7. The use any one of claims 4-6, wherein the DLBCL or WM is characterized by a L265P mutation in MYD88.

8. The use of any one of claims 1-3, wherein the cancer is a non-Hodgkin's lymphoma.

9. The use of claim 8, wherein the non-Hodgkin's lymphoma is selected from mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CNS lymphoma, and testicular lymphoma.

10. The use of any one of claims 1-3, wherein the cancer is leukemia.

11. The use of claim 10, wherein the leukemia is acute myeloid leukemia (AML).

12. The use of claim 10, wherein the leukemia is acute lymphoblastic leukemia (ALL).

13. The use of claim 10, wherein the leukemia is chronic lymphocytic leukemia (CLL).

14. The use of claim 10, wherein the leukemia is chronic myelogenous leukemia (CML).

15. The use of any one of claims 10-14, wherein the leukemia is a myelodysplastic syndrome.

16. The use of claim 15, wherein the myelodysplastic syndrome is selected from refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.

17. The use of any one of claims 1-3, wherein the cancer is a myeloproliferative neoplasm.

18. The use of claim 17, wherein the myeloproliferative neoplasm is selected from chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), polycythemia vera (PCV), primary myelofibrosis, essential thrombocythemia, chronic eosinophilic leukemia, and mastocytosis.

19. The use of any one of claims 1-3, wherein the cancer is a solid malignant tumor.

20. The use of claim 19, wherein the solid malignant tumor is selected from biliary cancer, cholangiocarcinoma, bladder cancer, breast cancer, adenocarcinoma of the breast, papillary carcinoma of the breast, mammary cancer, medullary carcinoma of the breast, brain cancer, meningioma, glioma, astrocytoma, oligodendroglioma, glioblastoma, medulloblastoma, cervical cancer, cervical adenocarcinoma, colorectal cancer, colon cancer, rectal cancer, colorectal adenocarcinoma, gastric cancer, stomach adenocarcinoma, gastrointestinal stromal tumor (GIST), head and neck cancer, head and neck squamous cell carcinoma, oral cancer, oral squamous cell carcinoma (OSCC), kidney cancer, nephroblastoma, Wilms' tumor, renal cell carcinoma, liver cancer, hepatocellular cancer (HCC), malignant hepatoma, lung cancer, bronchogenic carcinoma, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma of the lung, neuroblastoma, neurofibroma, neurofibromatosis (NF) type 1 or type 2, schwannomatosis, neuroendocrine cancer, gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoid tumor, osteosarcoma, ovarian cancer, cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma, pancreatic cancer, pancreatic andenocarcinoma, intraductal papillary mucinous neoplasm (IPMN), prostate cancer, prostate adenocarcinoma, skin cancer, squamous cell carcinoma (SCC), keratoacanthoma (A), melanoma, basal cell carcinoma (BCC), malignant fibrous histiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma, and osteosarcoma.

21. The use of claim 19, wherein the solid malignant tumor is breast cancer or pancreatic cancer.

22. The use of any one of claims 1-21, wherein the medicament is for administration with the venetoclax simultaneously.

23. The use of any one of claims 1-21, wherein the medicament is for administration within about 5 minutes to within about 168 hours prior to or after administration of the venetoclax.